APLS — Apellis Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.20bn
- $2.24bn
- $781.37m
- 33
- 23
- 23
- 15
Annual cashflow statement for Apellis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -345 | -746 | -652 | -529 | -198 |
| Depreciation | |||||
| Non-Cash Items | 164 | 275 | 153 | 132 | 126 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 19.6 | -93.5 | -15.7 | -200 | -18.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -160 | -563 | -514 | -595 | -87.9 |
| Capital Expenditures | -5.42 | -1.1 | -1.52 | -0.773 | -0.403 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -312 | 249 | 61.4 | 0.099 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -317 | 248 | 59.9 | -0.674 | -0.403 |
| Financing Cash Flow Items | -23.1 | -5.79 | -5.68 | -11 | 98.7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 692 | 392 | 366 | 394 | 149 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 215 | 74.7 | -88.7 | -201 | 60.3 |